

Listing of Claims:

1 – 5 (Cancelled)

6. (Currently Amended) A ~~vaccine~~ composition effective to ~~diminish~~ neutralize CMV infection comprising ~~at least a fragment of~~ glycoprotein O polypeptide in combination with a pharmacologically acceptable carrier.

7. (Cancelled)

8. (Currently Amended) The ~~vaccine~~ composition of claim 4 6 wherein the polypeptide has a deletion of all or a portion of the transmembrane anchor region.

9. (Currently Amended) A method of ~~vaccinating~~ treating a patient against CMV infection comprising administering the ~~vaccine~~ composition of claim 4 6 to the patient.

10. (Currently Amended) The method of claim 9 additionally comprising a step of administering at least one ~~vaccine~~ composition comprising at least a fragment of a glycoprotein selected from the group of CMV glycoprotein H, CMV glycoprotein L, and CMV glycoprotein B.

11. (Currently Amended) An anti-CMV drug comprising ~~of at least a fragment of~~ CMV glycoprotein O and a pharmacologically acceptable carrier.

Appl. No. 09/942,146
Amdt. Dated March 3, 2004
Reply to Office Action of November 18, 2003

12. (Original) The drug of claim 11 wherein the drug comprises full-length CMV glycoprotein O.

13 – 14 (Cancelled)